Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load
Autore:
Rubio, A; Gomez-Cano, M; Puig, T; Leal, M; Perez-Olmeda, M; Ruiz, L; Clotet, B; Rey, C; Zamora, L; Xaus, N; Soriano, V;
Indirizzi:
Virgen Rocio Univ Hosp, Viral Hepatitis & AIDS Study Grp, Seville, Spain Virgen Rocio Univ Hosp Seville Spain s & AIDS Study Grp, Seville, Spain Virgen Rocio Univ Hosp, Dept Biochem, Seville, Spain Virgen Rocio Univ Hosp Seville Spain Hosp, Dept Biochem, Seville, Spain Virgen Rocio Univ Hosp, Dept Med, Seville, Spain Virgen Rocio Univ Hosp Seville Spain niv Hosp, Dept Med, Seville, Spain Inst Salud Carlos III, Infect Dis Serv, Madrid, Spain Inst Salud Carlos III Madrid Spain III, Infect Dis Serv, Madrid, Spain Hosp Germans Trias & Pujol, Fundacio Irsi Caixa, Badalona, Spain Hosp Germans Trias & Pujol Badalona Spain o Irsi Caixa, Badalona, Spain Bristol Myers Squibb, Madrid, Spain Bristol Myers Squibb Madrid SpainBristol Myers Squibb, Madrid, Spain Murex, Madrid, Spain Murex Madrid SpainMurex, Madrid, Spain
Titolo Testata:
ANTIVIRAL THERAPY
fascicolo: 1, volume: 4, anno: 1999,
pagine: 45 - 49
SICI:
1359-6535(1999)4:1<45:POGRIN>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
VIRUS TYPE-1 RNA; ANTIRETROVIRAL THERAPY; PLASMA; ASSAY; HIV; REPLICATION; SENSITIVITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Leal, M Virgen Rocio Univ Hosp, Viral Hepatitis & AIDS Study Grp, Seville,Spain Virgen Rocio Univ Hosp Seville Spain Study Grp, Seville, Spain
Citazione:
A. Rubio et al., "Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load", ANTIVIR TH, 4(1), 1999, pp. 45-49

Abstract

Patients harbouring drug-resistant viruses usually suffer a rise in serum viraemia after a variable period of time. We have investigated the relationship between the appearance of resistant genotypes and the viral load of each patient after treatment, Our objective was to assess the association between human immunodeficiency virus (HIV) RNA plasma levels and the number ofdrug resistance-associated point mutations after treatment. A total of 150patients from three reference centres in Spain (Madrid, Barcelona and Seville) from a previous study (Erase Study) were included. Patients had at that time undergone antiretroviral treatment with nucleoside analogues for at least 1 year (zidovudine/didanosine; zidovudine/zalcitabine; zidovudine/zalcitabine/lamivudine; zidovudine/didanosine/lamivudine). In this study, plasma viraemia in these patients was quantified and a line probe assay was used to determine the genotype of the virus. Viral load was significantly higher in patients harbouring virus with more than three mutations than in those individuals who harboured wild-type strains (P<0.05). Surprisingly, when patients with viral load <500 copies/mt (13/150) were analysed, only two carried wildtype strains, whereas three had virus with more than three point mutations. The viral load of six samples was assayed using an ultrasensitive test (detection limit <20 copies/ml). Of the three samples where viral load was <20 copies/ml, one patient harboured wild-type virus, whereas two carried mutant virus strains. These results suggest that even in patients with undetectable viral loads by conventional methods, viral replication may continue and mutations develop. Therefore, standard values of plasma viraemia for measuring the effectiveness of the treatment should be reconsidered when patients are on antiviral regimens of just two or three nucleoside analogues.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/06/20 alle ore 23:46:46